"As you can see there are many questions that need answering and we would like your input to answer them. The purpose of this study is to explore whether or not our candidate drugs do what the meant to do to on the target viruses in MSers and to show that there are no major safety issues. Further thoughts please?"
"The survey is still open and we have expanded the number of questions we are asking; we need more responses in relation to the type of funding model and whether or not you you understand what we are trying to do."
"Please note although we are going with the Charcot 2 Project we are still working on the HSCT vs. Alemtuzumab or the ZEUS study. At the moment we are engaging with Dr Paolo Muraro's group at Imperial who will need to lead on this."